{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:45:56Z","timestamp":1782499556928,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["TTU-TB 02.716"],"award-info":[{"award-number":["TTU-TB 02.716"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-resistant tuberculosis remains a major health challenge, with treatment success for multidrug- or rifampicin-resistant (MDR\/RR) disease substantially lower than for drug-susceptible tuberculosis. Access to accurate and timely drug susceptibility testing (DST) is essential for designing effective treatment regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of adults with pulmonary tuberculosis treated at the Research Center Borstel in Germany between March 2019 and November 2021. Patients with culture-confirmed tuberculosis and either fully drug-susceptible disease or phenotypically confirmed MDR\/RR tuberculosis were included. Comprehensive phenotypic DST (pDST) and molecular DST (mDST) by whole-genome sequencing (WGS) were performed. Treatment outcomes were assessed using the WHO 2021 definitions as the primary endpoint, with TBnet outcome definitions evaluated secondarily. Firth's penalized logistic regression identified predictors of cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-six patients were included: 43 with drug-susceptible tuberculosis and 23 with MDR\/RR tuberculosis. Concordance between pDST and WGS-based mDST was high. In drug-susceptible disease, 13 (30%) were cured and 28 (65%) completed treatment, resulting in a WHO-defined success rate of 95%; 33 (77%) met TBnet cure criteria. Among MDR\/RR patients, four (17%) were cured and 16 (70%) completed treatment, yielding a WHO-defined success rate of 87%; 19 (83%) were cured per TBnet criteria. No significant predictors of cure were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this high-resource setting with access to comprehensive pDST and mDST, patients with MDR\/RR tuberculosis achieved outcomes comparable to those with drug-susceptible disease. High concordance between phenotypic and molecular DST supports the reliability of mDST for guiding individualized treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag349","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:46:15Z","timestamp":1780659975000},"source":"Crossref","is-referenced-by-count":0,"title":["Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant Tuberculosis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-161X","authenticated-orcid":false,"given":"Thomas Theo","family":"Brehm","sequence":"first","affiliation":[{"name":"Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]},{"name":"German Center for Infection Research (DZIF) , Hamburg-L\u00fcbeck-Borstel-Riems ,","place":["Germany"]},{"name":"Division of Infectious Diseases, I. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6059-4086","authenticated-orcid":false,"given":"Dagmar","family":"Schaub","sequence":"additional","affiliation":[{"name":"Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-3693","authenticated-orcid":false,"given":"Viola","family":"Dreyer","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF) , Hamburg-L\u00fcbeck-Borstel-Riems ,","place":["Germany"]},{"name":"Molecular and Experimental Mycobacteriology, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"K\u00f6hler","sequence":"additional","affiliation":[{"name":"Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]},{"name":"German Center for Infection Research (DZIF) , Hamburg-L\u00fcbeck-Borstel-Riems ,","place":["Germany"]},{"name":"Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Center for Clinical Studies, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-8356","authenticated-orcid":false,"given":"Martin","family":"Kuhns","sequence":"additional","affiliation":[{"name":"Molecular and Experimental Mycobacteriology, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian P","family":"Maurer","sequence":"additional","affiliation":[{"name":"National and WHO Supranational Reference Laboratory for Mycobacteria, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]},{"name":"Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[{"name":"Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]},{"name":"German Center for Infection Research (DZIF) , Hamburg-L\u00fcbeck-Borstel-Riems ,","place":["Germany"]},{"name":"Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Respiratory Medicine and International Health, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]},{"name":"Baylor College of Medicine, Global TB Program, Department of Pediatrics , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kalsdorf","sequence":"additional","affiliation":[{"name":"Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center , Borstel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2026062613472764900_ofag349-B1","volume-title":"Global tuberculosis report 2025","year":"2025"},{"key":"2026062613472764900_ofag349-B2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/cid\/civ910","article-title":"Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance","volume":"62","author":"Cegielski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026062613472764900_ofag349-B3"},{"key":"2026062613472764900_ofag349-B4","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/cid\/ciab359","article-title":"Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing","volume":"73","author":"Grobbel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026062613472764900_ofag349-B5","volume-title":"Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis","author":"World Health Organization","year":"2018"},{"key":"2026062613472764900_ofag349-B6","volume-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2014"},{"key":"2026062613472764900_ofag349-B7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1128\/jcm.29.11.2578-2586.1991","article-title":"Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis","volume":"29","author":"van Soolingen","year":"1991","journal-title":"J Clin Microbiol"},{"key":"2026062613472764900_ofag349-B8","doi-asserted-by":"crossref","first-page":"e0128036","DOI":"10.1371\/journal.pone.0128036","article-title":"Inexpensive multiplexed library preparation for megabase-sized genomes","volume":"10","author":"Baym","year":"2015","journal-title":"PLoS One"},{"key":"2026062613472764900_ofag349-B9","doi-asserted-by":"crossref","first-page":"e5895","DOI":"10.7717\/peerj.5895","article-title":"MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates","volume":"6","author":"Kohl","year":"2018","journal-title":"PeerJ"},{"key":"2026062613472764900_ofag349-B10","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","year":"2023","edition":"2nd ed"},{"key":"2026062613472764900_ofag349-B11","volume-title":"Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17\u201319 November 2020","year":"2021"},{"key":"2026062613472764900_ofag349-B12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMc1603274","article-title":"Treatment outcomes in multidrug-resistant tuberculosis","volume":"375","author":"G\u00fcnther","year":"2016","journal-title":"N Engl J Med"},{"key":"2026062613472764900_ofag349-B13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"Lancet"},{"key":"2026062613472764900_ofag349-B14","volume-title":"WHO Consolidated guidelines on tuberculosis. Module 4: treatment and care","author":"World Health Organization","year":"2025"},{"key":"2026062613472764900_ofag349-B15","year":"2021"},{"key":"2026062613472764900_ofag349-B16","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S1473-3099(22)00875-1","article-title":"Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet\/RESIST-TB consensus statement","volume":"23","author":"Dom\u00ednguez","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026062613472764900_ofag349-B17","doi-asserted-by":"crossref","first-page":"1197.e1","DOI":"10.1016\/j.cmi.2024.03.009","article-title":"Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe","volume":"30","author":"G\u00fcnther","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026062613472764900_ofag349-B18"},{"key":"2026062613472764900_ofag349-B19","doi-asserted-by":"crossref","first-page":"2100621","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"},{"key":"2026062613472764900_ofag349-B20","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026062613472764900_ofag349-B21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3201\/eid3003.240134","article-title":"Bedaquiline resistance after effective treatment of multidrug-resistant tuberculosis, Namibia","volume":"30","author":"G\u00fcnther","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2026062613472764900_ofag349-B22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3201\/eid3103.241675","article-title":"Fluoroquinolone resistance in drug-resistant tuberculosis, Kharkiv, Ukraine, 2019\u20132023","volume":"31","author":"Konstantynovska","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"2026062613472764900_ofag349-B23","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1093\/cid\/ciaf495","article-title":"Cost-effectiveness of targeted next generation sequencing for TB drug-resistance testing as an alternative to the standard of care in South Africa","volume":"82","author":"de Nooy","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026062613472764900_ofag349-B24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1473-3099(24)00263-9","article-title":"Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"24","author":"Schwab","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026062613472764900_ofag349-B25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible Tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062613472764900_ofag349-B26","author":"Conradie"},{"key":"2026062613472764900_ofag349-B27","volume-title":"Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024","year":"2024"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag349\/68519777\/ofag349.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag349\/68519777\/ofag349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag349\/68519777\/ofag349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:47:35Z","timestamp":1782496055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag349\/8707220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag349","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag349"}}